Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) has received an average recommendation of “Buy” from the six brokerages that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $26.00.
Several brokerages have commented on AGLE. Wells Fargo & Co cut shares of Aeglea Bio Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, September 4th. Zacks Investment Research cut shares of Aeglea Bio Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 14th. Finally, BMO Capital Markets assumed coverage on shares of Aeglea Bio Therapeutics in a report on Thursday, June 14th. They set an “outperform” rating and a $21.00 price target for the company.
Shares of AGLE traded up $0.05 during midday trading on Friday, hitting $9.79. The stock had a trading volume of 274,879 shares, compared to its average volume of 205,588. Aeglea Bio Therapeutics has a fifty-two week low of $3.75 and a fifty-two week high of $12.00. The stock has a market cap of $211.32 million, a price-to-earnings ratio of -5.44 and a beta of 0.16.
In related news, insider Aaron Schuchart sold 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 27th. The shares were sold at an average price of $9.50, for a total transaction of $57,000.00. Following the completion of the sale, the insider now directly owns 8,400 shares in the company, valued at $79,800. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 18.30% of the company’s stock.
Several hedge funds have recently bought and sold shares of the stock. Spark Investment Management LLC boosted its holdings in shares of Aeglea Bio Therapeutics by 69.6% during the first quarter. Spark Investment Management LLC now owns 19,000 shares of the biotechnology company’s stock worth $188,000 after purchasing an additional 7,800 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in shares of Aeglea Bio Therapeutics during the second quarter worth approximately $131,000. Rhumbline Advisers acquired a new stake in shares of Aeglea Bio Therapeutics during the second quarter worth approximately $161,000. Blair William & Co. IL boosted its holdings in shares of Aeglea Bio Therapeutics by 142.8% during the first quarter. Blair William & Co. IL now owns 27,204 shares of the biotechnology company’s stock worth $270,000 after purchasing an additional 16,000 shares during the period. Finally, A.R.T. Advisors LLC acquired a new stake in shares of Aeglea Bio Therapeutics during the first quarter worth approximately $183,000. Institutional investors and hedge funds own 66.50% of the company’s stock.
Aeglea Bio Therapeutics Company Profile
Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.
Featured Article: Asset Allocation
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.